Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -1.56% lower on its value in year-to-date trading and has touched a low of $4.71 and a high of $9.74 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $8.71 in the last trading session, with the day’s gains setting it 0.14%.
Currently trading at $8.85, the stock is 8.51% and 17.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing 1.61% at the moment leaves the stock 45.14% off its SMA200. AUPH registered 1.84% gain for a year compared to 6-month gain of 64.50%. The firm has a 50-day simple moving average (SMA 50) of $7.532 and a 200-day simple moving average (SMA200) of $6.09765.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 18.16% loss in the last 1 month and extending the period to 3 months gives it a 28.26%, and is 7.40% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.66% over the week and 4.12% over the month.
Aurinia Pharmaceuticals Inc (AUPH) has around 300 employees, a market worth around $1.29B and $220.36M in sales. Fwd P/E is 15.04. Profit margin for the company is -10.23%. Distance from 52-week low is 87.90% and -9.14% from its 52-week high. The company has generated returns on investments over the last 12 months (-4.90%).
Aurinia Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at 0.0 with sales reaching $59.94M over the same period.The EPS is expected to grow by 105.86% this year, but quarterly earnings will post 34.20% year-over-year. Quarterly sales are estimated to grow 32.93% in year-over-year returns.
258.0 institutions hold shares in Aurinia Pharmaceuticals Inc (AUPH), with institutional investors hold 46.04% of the company’s shares. The shares outstanding are 143.83M, and float is at 128.71M with Short Float at 5.34%. Institutions hold 42.73% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 11.14 million shares valued at $63.59 million. The investor’s holdings represent 7.7326 of the AUPH Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.27 million shares valued at $52.94 million to account for 6.4384 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 3.97 million shares representing 2.7566 and valued at over $22.67 million, while STATE STREET CORP holds 1.9999 of the shares totaling 2.88 million with a market value of $16.45 million.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
The most recent transaction is an insider sale by Bailey Jeffrey Allen, the company’s Director. SEC filings show that Bailey Jeffrey Allen sold 4,557 shares of the company’s common stock on Nov 11 ’24 at a price of $8.43 per share for a total of $38416.0. Following the sale, the insider now owns 13356.0 shares.
Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 11 ’24 that Smith Karen L. (Director) sold a total of 5,241 shares of the company’s common stock. The trade occurred on Nov 11 ’24 and was made at $8.43 per share for $44182.0. Following the transaction, the insider now directly holds 12672.0 shares of the AUPH stock.
Still, SEC filings show that on Aug 06 ’24, Habig Scott Michael (Chief Commercial Officer) disposed off 18,249 shares at an average price of $5.31 for $96902.0. The insider now directly holds 456,338 shares of Aurinia Pharmaceuticals Inc (AUPH).
